Has anyone considered a "worst" case scenario. A slow uptake on NuGenerex Distribution Solutions ... Seems like building out these networks is time consuming and costly. There is a lot of infrastructure involved. NuGenerex Immuno-Oncology being eclipsed by other technologies (mRNA) with more market power that stagnate/suppress NGIO growth. Slow market infiltration for NuGenerex Therapeutics for lack of funds needed to market and educate doctors ... What are the probabilities of any or all of these occurring? The timelines put out by Joe always seem optimistic ... or best case scenario ... Maybe we should start developing a realistic timeline for expectations.